<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814824</url>
  </required_header>
  <id_info>
    <org_study_id>18-0963</org_study_id>
    <nct_id>NCT03814824</nct_id>
  </id_info>
  <brief_title>Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)</brief_title>
  <official_title>Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS): a Multi-center Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NinePoint Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial examining how IRIS (Intelligent Real-time
      Image Segmentation) affects biopsy patterns in VLE (Volumetric laser endomicroscopy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo a VLE exam with and without IRIS per the standard of care. All patients
      regardless of the study participation in this study would receive VLE with and without IRIS
      clinically. They will be randomized into VLE without IRIS first vs VLE with IRIS first. The
      BUDDY Randomization System, provided for use by the Northwell Health Biostatistics Unit, will
      be used for this. Randomization will be stratified based on prior diagnosis of dysplasia. The
      order in which the patient is randomized to will be recorded on the case report form. There
      will be concealed allocation as the study coordinator performing the randomization will not
      know the order of the next allocation.

      Both VLE and IRIS imaging are being performed as standard of care. However, randomization of
      the order allows for comparison of the two. Regions of interest (ROI) will be recorded using
      a full scan and recorded on the case report form. The time to identification of ROIs will
      also be recorded. Each group will then cross over such that the VLE without IRIS group will
      then have IRIS turned on. ROI will then be recorded for each group based on full scans. A
      consensus ROI will be recorded based on the two exams. Only one ROI per centimeter will be
      allowed to avoid overlapping of laser marks. In addition, VLE without IRIS and IRIS marks
      within 75 frames of each other or 2 hours (on a clock face orientation) will be considered
      the same target.

      Laser marking will then be performed. A double laser mark will be applied to all IRIS ROIs. A
      single laser mark will be applied to VLE ROIs. Targeted biopsies will be taken of all laser
      marks and placed in separate biopsy jars. Biopsies will be taken in between the laser marks
      for double laser marked areas. For single laser marks, biopsies will be taken on either side
      of the laser mark. Resection of visible lesions will then occur per standard of care (if
      present) followed by random biopsies of the segment. Random biopsies are pinch biopsies every
      1 cm the length of the Barrett's in a 4 quadrant fashion per gastrointestinal society
      guidelines. There are no additional research biopsies being performed outside this study. The
      targeted biopsies are based on the VLE features that are suspicious for dysplasia and thus
      standard of care. The other biopsies being performed here are random biopsies which are also
      being performed for standard of care. Biopsied samples will be stored per standard of care
      procedures per the pathology department. They will not be stored for future research
      purposes.

      Following each procedure, the physician will be asked a series of Likert Scale questions to
      assess the utility of IRIS in that procedure, including how it impacts their confidence in
      image interpretation, their ability to assimilate data more easily and quickly, and their
      overall perception of the technology.

      Although, the VLE with IRIS and VLE without IRIS are being performed as standard of care, all
      adverse events will be recorded and reported to the IRB.

      All data will be entered into a central encrypted REDCap database.

      Expert pathologists who specialize in gastrointestinal pathology will read the histology. A
      second gastrointestinal pathologist will confirm any histologic diagnosis of dysplasia. This
      is the standard of care at Northwell Health and academic medical centers per gastrointestinal
      society guidelines.

      All procedures (upper endoscopy, volumetric laser endomicroscopy, and IRIS enhanced VLE) will
      be performed as standard of care. The prospective data collection and initial randomization
      will be the research component. All data collected will be de-identified before being
      transferred into a database. This will be kept in a safe place that is only accessible to the
      research team.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for image interpretation</measure>
    <time_frame>During the procedure</time_frame>
    <description>Time will be a surrogate for ease of interpretation. Time will be recorded from start of image interpretation to the end of image interpretation. Length of Barrett's will be taken into account (time per cm of Barrett's) when comparing this outcome between patients and procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy yield</measure>
    <time_frame>During the procedure</time_frame>
    <description>Biopsy yield (in terms of dysplasia present versus not present) of IRIS biopsies (double laser mark) will be compared to VLE without IRIS biopsies (single laser mark) and random biopsies (taken every 1cm in a four quadrant fashion throughout the length of the Barrett's).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of biopsies</measure>
    <time_frame>at time of initial study procedure</time_frame>
    <description>Total number of targeted and random biopsies taken during each procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Barrett's Esophagus Without Dysplasia</condition>
  <condition>Barrett's Esophagus With Dysplasia</condition>
  <condition>Barrett's Esophagus With Low Grade Dysplasia</condition>
  <condition>Barrett's Esophagus With High Grade Dysplasia</condition>
  <condition>Barrett's Esophagus With Dysplasia, Unspecified</condition>
  <arm_group>
    <arm_group_label>VLE without IRIS, followed by VLE with IRIS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLE with IRIS, followed by VLE without IRIS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IRIS (Intelligent real-time image segmentation)</intervention_name>
    <description>IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.</description>
    <arm_group_label>VLE with IRIS, followed by VLE without IRIS</arm_group_label>
    <arm_group_label>VLE without IRIS, followed by VLE with IRIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VLE (Volumetric laser endomicroscopy)</intervention_name>
    <description>VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.</description>
    <arm_group_label>VLE with IRIS, followed by VLE without IRIS</arm_group_label>
    <arm_group_label>VLE without IRIS, followed by VLE with IRIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older at the time of informed consent

          -  Barrett's esophagus greater than 2 cm in length

          -  Undergoing a scheduled upper endoscopy with VLE exam for surveillance as standard of
             care

        Exclusion Criteria:

          -  Less than 18 years old at the time of informed consent

          -  Unable to provide written informed consent

          -  Esophageal stenosis/stricture preventing VLE

          -  Esophagitis

          -  Severe medical comorbidities preventing endoscopy

          -  Pregnancy

          -  Uncontrolled coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arvind Trindade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arvind Trindade, MD</last_name>
    <phone>718-470-7997</phone>
    <email>atrindade@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly Stewart, BS</last_name>
    <phone>516-600-1443</phone>
    <email>mstewart8@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Stewart, BS</last_name>
      <phone>516-600-1443</phone>
      <email>mstewart8@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Arvind Trindade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51. doi: 10.1038/ajg.2015.322. Epub 2015 Nov 3. Erratum in: Am J Gastroenterol. 2016 Jul;111(7):1077.</citation>
    <PMID>26526079</PMID>
  </reference>
  <reference>
    <citation>Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014 Aug 28;371(9):836-45. doi: 10.1056/NEJMra1314704. Review.</citation>
    <PMID>25162890</PMID>
  </reference>
  <reference>
    <citation>Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005 Jan 19;97(2):142-6.</citation>
    <PMID>15657344</PMID>
  </reference>
  <reference>
    <citation>Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, Bannon F, Hicks B, Kennedy G, Gavin AT, Murray LJ. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut. 2015 Jan;64(1):20-5. doi: 10.1136/gutjnl-2013-305506. Epub 2014 Apr 3.</citation>
    <PMID>24700439</PMID>
  </reference>
  <reference>
    <citation>Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013 Aug;145(2):312-9.e1. doi: 10.1053/j.gastro.2013.05.004. Epub 2013 May 11.</citation>
    <PMID>23673354</PMID>
  </reference>
  <reference>
    <citation>Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 1993 Jul;105(1):40-50.</citation>
    <PMID>8514061</PMID>
  </reference>
  <reference>
    <citation>Jankowski M, Wani S. Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus. Curr Treat Options Gastroenterol. 2015 Mar;13(1):16-29. doi: 10.1007/s11938-014-0040-9.</citation>
    <PMID>25567106</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Smith MS, Pleskow DK. The new kid on the block for advanced imaging in Barrett's esophagus: a review of volumetric laser endomicroscopy. Therap Adv Gastroenterol. 2016 May;9(3):408-16. doi: 10.1177/1756283X16639003. Epub 2016 Mar 21. Review.</citation>
    <PMID>27134668</PMID>
  </reference>
  <reference>
    <citation>Wolfsen HC, Sharma P, Wallace MB, Leggett C, Tearney G, Wang KK. Safety and feasibility of volumetric laser endomicroscopy in patients with Barrett's esophagus (with videos). Gastrointest Endosc. 2015 Oct;82(4):631-40. doi: 10.1016/j.gie.2015.03.1968. Epub 2015 May 6.</citation>
    <PMID>25956472</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Leggett CL, Chang KJ. Volumetric laser endomicroscopy in the management of Barrett's esophagus. Curr Opin Gastroenterol. 2017 Jul;33(4):254-260. doi: 10.1097/MOG.0000000000000366. Review.</citation>
    <PMID>28402993</PMID>
  </reference>
  <reference>
    <citation>Swager AF, de Groof AJ, Meijer SL, Weusten BL, Curvers WL, Bergman JJ. Feasibility of laser marking in Barrett's esophagus with volumetric laser endomicroscopy: first-in-man pilot study. Gastrointest Endosc. 2017 Sep;86(3):464-472. doi: 10.1016/j.gie.2017.01.030. Epub 2017 Feb 2.</citation>
    <PMID>28161451</PMID>
  </reference>
  <reference>
    <citation>Swager AF, Tearney GJ, Leggett CL, van Oijen MGH, Meijer SL, Weusten BL, Curvers WL, Bergman JJGHM. Identification of volumetric laser endomicroscopy features predictive for early neoplasia in Barrett's esophagus using high-quality histological correlation. Gastrointest Endosc. 2017 May;85(5):918-926.e7. doi: 10.1016/j.gie.2016.09.012. Epub 2016 Sep 19.</citation>
    <PMID>27658906</PMID>
  </reference>
  <reference>
    <citation>Leggett CL, Gorospe EC, Chan DK, Muppa P, Owens V, Smyrk TC, Anderson M, Lutzke LS, Tearney G, Wang KK. Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett's esophagus. Gastrointest Endosc. 2016 May;83(5):880-888.e2. doi: 10.1016/j.gie.2015.08.050. Epub 2015 Sep 3.</citation>
    <PMID>26344884</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Vamadevan AS, Sejpal DV. Finding a needle in a haystack: use of volumetric laser endomicroscopy in targeting focal dysplasia in long-segment Barrett's esophagus. Gastrointest Endosc. 2015 Oct;82(4):756; discussion 757. doi: 10.1016/j.gie.2015.03.1984. Epub 2015 May 21.</citation>
    <PMID>26005011</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, George BJ, Berkowitz J, Sejpal DV, McKinley MJ. Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett's esophagus. Endosc Int Open. 2016 Mar;4(3):E318-22. doi: 10.1055/s-0042-101409.</citation>
    <PMID>27004250</PMID>
  </reference>
  <reference>
    <citation>Leggett CL, Gorospe E, Owens VL, Anderson M, Lutzke L, Wang KK. Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. Am J Gastroenterol. 2014 Feb;109(2):298-9. doi: 10.1038/ajg.2013.422.</citation>
    <PMID>24496431</PMID>
  </reference>
  <reference>
    <citation>Swager AF, Boerwinkel DF, de Bruin DM, Faber DJ, van Leeuwen TG, Weusten BL, Meijer SL, Bergman JJ, Curvers WL. Detection of buried Barrett's glands after radiofrequency ablation with volumetric laser endomicroscopy. Gastrointest Endosc. 2016 Jan;83(1):80-8. doi: 10.1016/j.gie.2015.05.028. Epub 2015 Jun 26.</citation>
    <PMID>26124075</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Sideridis K, Thomas RM. Buried Barrett's Esophagus Presenting as a Subepithelial Nodule. Am J Gastroenterol. 2016 Oct;111(10):1378. doi: 10.1038/ajg.2016.242.</citation>
    <PMID>27694877</PMID>
  </reference>
  <reference>
    <citation>Mashimo H. Subsquamous intestinal metaplasia after ablation of Barrett's esophagus: frequency and importance. Curr Opin Gastroenterol. 2013 Jul;29(4):454-9. doi: 10.1097/MOG.0b013e3283622796. Review.</citation>
    <PMID>23674187</PMID>
  </reference>
  <reference>
    <citation>Atkinson C, Singh S, Fisichella PM. Volumetric laser endomicroscopy in the detection of neoplastic lesions of the esophagus. Dig Liver Dis. 2016 Jun;48(6):692. doi: 10.1016/j.dld.2016.02.013. Epub 2016 Mar 2.</citation>
    <PMID>26976783</PMID>
  </reference>
  <reference>
    <citation>Alshelleh M, Inamdar S, McKinley M, Stewart M, Novak JS, Greenberg RE, Sultan K, Devito B, Cheung M, Cerulli MA, Miller LS, Sejpal DV, Vegesna AK, Trindade AJ. Incremental yield of dysplasia detection in Barrett's esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc. 2018 Jul;88(1):35-42. doi: 10.1016/j.gie.2018.01.032. Epub 2018 Feb 2.</citation>
    <PMID>29410080</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Inamdar S, Smith MS, Chang KJ, Leggett CL, Lightdale CJ, Pleskow DK, Sejpal DV, Tearney GJ, Thomas RM, Wallace MB. Volumetric laser endomicroscopy in Barrett's esophagus: interobserver agreement for interpretation of Barrett's esophagus and associated neoplasia among high-frequency users. Gastrointest Endosc. 2017 Jul;86(1):133-139. doi: 10.1016/j.gie.2016.11.026. Epub 2016 Nov 27.</citation>
    <PMID>27899321</PMID>
  </reference>
  <reference>
    <citation>Trindade AJ, Inamdar S, Smith MS, Rosen L, Han D, Chang KJ, Leggett CL, Lightdale CJ, Pleskow DK, Sejpal DV, Tearney GJ, Thomas RM, Wallace MB. Learning curve and competence for volumetric laser endomicroscopy in Barrett's esophagus using cumulative sum analysis. Endoscopy. 2018 May;50(5):471-478. doi: 10.1055/s-0043-121569. Epub 2017 Nov 27. Erratum in: Endoscopy. 2018 May;50(5):C10.</citation>
    <PMID>29179229</PMID>
  </reference>
  <reference>
    <citation>Evans JA, Poneros JM, Bouma BE, Bressner J, Halpern EF, Shishkov M, Lauwers GY, Mino-Kenudson M, Nishioka NS, Tearney GJ. Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol. 2006 Jan;4(1):38-43.</citation>
    <PMID>16431303</PMID>
  </reference>
  <reference>
    <citation>Swager AF, van der Sommen F, Klomp SR, Zinger S, Meijer SL, Schoon EJ, Bergman JJGHM, de With PH, Curvers WL. Computer-aided detection of early Barrett's neoplasia using volumetric laser endomicroscopy. Gastrointest Endosc. 2017 Nov;86(5):839-846. doi: 10.1016/j.gie.2017.03.011. Epub 2017 Mar 16.</citation>
    <PMID>28322771</PMID>
  </reference>
  <reference>
    <citation>Alvarez Herrero L, Curvers WL, van Vilsteren FG, Wolfsen H, Ragunath K, Wong Kee Song LM, Mallant-Hent RC, van Oijen A, Scholten P, Schoon EJ, Schenk EB, Weusten BL, Bergman JG. Validation of the Prague C&amp;M classification of Barrett's esophagus in clinical practice. Endoscopy. 2013 Nov;45(11):876-82. doi: 10.1055/s-0033-1344952. Epub 2013 Oct 28.</citation>
    <PMID>24165812</PMID>
  </reference>
  <reference>
    <citation>The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43. Review.</citation>
    <PMID>14652541</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLE</keyword>
  <keyword>Volumetric laser endomicroscopy</keyword>
  <keyword>IRIS</keyword>
  <keyword>Intelligent real-time image segmentation</keyword>
  <keyword>Barrett's Esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

